Research Article
No access
Published Online: 15 July 2019

TIR-TLR7 as a Molecular Adjuvant: Simultaneous Enhancing Humoral and Cell-Mediated Immune Responses Against Inactivated Infectious Bursal Disease Virus

Publication: Viral Immunology
Volume 32, Issue Number 6

Abstract

Despite the robust induction of humoral immune responses, a limitation of many adjuvants is their weak stimulation of cellular immunity. The development of synthetic gene-encoding adjuvants for simultaneous induction of both humoral and cell-mediated immune responses is under study. In this study, we examined the impact of toll/interleukin-1 receptor (TIR) domain of toll-like receptor 7 (TLR7) as molecular adjuvants on potency of inactivated infectious bursal disease (IBD) vaccines. A total of 60 specific pathogen-free week-old chicks were randomized grouped to receive either TIR-TLR7-adjuvanted IBD-inactivated vaccine or inactivated IBD antigen along with an unvaccinated control. Serum antibody titers were measured to estimate the humoral immunity, as well as lymphocyte proliferation activity for cellular immune responses. The protection was estimated after challenge with a very virulent IBD virus (IBDV) strain at 4 weeks postvaccination. The results indicated that one dose of IBD/TIR-TLR7 vaccine induced specific antibody responses, whereas a lower response after administration of inactivated IBD antigen was observed. The stimulation of splenocytes results indicated that the TIR-TLR7 adjuvanted IBD vaccine is capable of modulating cell-mediated immune response in treated chickens. A full protection against IBDV infection was achieved by injection of one dose IBD/TIR-TLR7 vaccine in the challenge trial. This study demonstrated that codelivery of TIR-TLR7 with inactivated IBD antigen resulted in simultaneous enhancing immune responses against IBD.

Get full access to this article

View all available purchase options and get full access to this article.

References

1. Di Pasquale A, Preiss S, Tavares Da Silva F, and Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines 2015;3:320–343.
2. Asif M, Jenkins KA, Hilton LS, Kimpton WG, Bean AG, and Lowenthal JW. Cytokines as adjuvants for avian vaccines. Immunol Cell Biol 2004;82:638–643.
3. Bao M, and Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 2013;4:40–52.
4. Barr TA, Brown S, Ryan G, Zhao J, and Gray D. TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. Eur J Immunol 2007;37:3040–3053.
5. Berg TPVD. Acute infectious bursal disease in poultry: a review. Avian Pathol 2000;29:175–194.
6. Colonna M. TLR pathways and IFN-regulatory factors: to each its own. Eur J Immounol 2007;37:306–309.
7. Dowling JK, and Mansell A. Toll-like receptors: the Swiss army knife of immunity and vaccine development. Clin Transl Immunology 2016;5:e85.
8. Ebrahimi MM, Shahsavandi S, Shayan P, Goudarzi H, and Masoudi S. An immunoinformatic assay to design bio adjuvanted vaccine against infectious bursal disease virus. J Biol Today's World 2016;5:13–19.
9. Ebrahimi MM, Shahsavandi S, Shayan P, Goudarzi H, and Masoudi S. Recombinant VP2 expressed in baculovirus and adjuvanted with TIR-TLR7: a vaccine candidate against infectious bursal disease virus. Comp Clin Pathol 2018;27:911–916.
10. Gupta SK, Deb R, Dey S, and Chellappa MM. Toll-like receptor-based adjuvants: enhancing the immune response to vaccines against infectious diseases of chicken. Expert Rev Vaccines 2014;13:909–925.
11. Guven-Maiorov E, Keskin O, Gursoy A, et al. The architecture of the TIR domain signalosome in the Toll-like Receptor-4 signaling pathway. Sci Rep 2018;5:13128.
12. Kannaki T, Reddy M, Shanmugam M, Verma P, and Sharma R. Chicken Toll like receptors and their role in immunity. World's Poult Sci J 2010;66:727–738.
13. Kong N, Wang X, Zhao J, Hu J, Zhang H, and Zhao H. A recombinant baculovirus expressing VP2 protein of infectious bursal disease virus (IBDV) and chicken Interleukin-18 (ChIL-18) protein protects against very virulent IBDV. J Anim Vet Adv 2011;10:2706–2715.
14. Lahiri A, Das P, and Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008;26:6777–6783.
15. Liang J, Yin Y, Qin T, and Yang Q. Chicken bone marrow-derived dendritic cells maturation in response to infectious bursal disease virus. Vet Immunol Immunop 2015;164:51–55.
16. Mahgoub HA. An overview of infectious bursal disease. Arch Virol 2012;157:2047–2057.
17. Müller H, Mundt E, Eterradossi N, and Islam MR. Current status of vaccines against infectious bursal disease. Avian Pathol 2012;41:133–139.
18. Nishiya T, Kajita E, Horinouchi T, Nishimoto A, and Miwa S. Distinct roles of TIR and non-TIR regions in the subcellular localization and signaling properties of MyD88. FEBS Lett 2007;581:3223–3229.
19. Park JH, Sung HW, Yoon BI, and Kwon HM. Protection of chicken against very virulent IBDV provided by in ovo priming with DNA vaccine and boosting with killed vaccine and the adjuvant effects of plasmid-encoded chicken interleukin-2 and interferon-γ. J Vet Sci 2009;10:131–139.
20. Philbin VJ, Iqbal M, Boyd Y, et al. Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens. Immunol 2005;114:507–521.
21. Rautenschlein S, Kraemer Ch, Vanmarcke J, and Montiel E. Protective efficacy of intermediate and intermediate plus infectious bursal disease virus (IBDV) vaccines against very virulent IBDV in commercial broilers. Avian Dis 2005;49:231–237.
22. Rautenschlein S, Yeh HY, Njenga MK, and Sharma JM. Role of intrabursal T cells in infectious bursal disease virus infection: T cells promote viral clearance but delay follicular recovery. Arch Virol 2002;147:285–304.
23. Schijns VE, Weining KC, Nuijten P, Rijke EO, and Staeheli P. Immunoadjuvant activities of E. coli- and plasmid-expressed recombinant chicken IFN-alpha/beta, IFN-gamma and IL-1beta in 1-day- and 3-week-old chickens. Vaccine 2000;18:2147–2154.
24. Sharma JM, Kim I-J, Rautenschlein S, and Yeh H-Y. Infectious bursal disease virus of chickens: pathogenesis and immunosuppression. Dev Comp Immunol 2000;24:223–235.
25. Teena M, Priyanka V, and Nageswara DR. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 2013;138:779–795.
26. Tovey MG, and Lallemand C. Adjuvant activity of cytokines. Methods Mol Biol 2010;626:287–309.
27. van Duin D, Medzhitov R, and Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49–55.
28. Ve T, Williams SJ, and Kobe B. Structure and function of Toll/interleukin-1 receptor/resistance protein (TIR) domains. Apoptosis 2015;20:250–261.

Information & Authors

Information

Published In

cover image Viral Immunology
Viral Immunology
Volume 32Issue Number 6July/August 2019
Pages: 252 - 257
PubMed: 31107184

History

Published online: 15 July 2019
Published in print: July/August 2019
Published ahead of print: 20 May 2019

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Mohammad Majid Ebrahimi [email protected]
Poultry Research and Viral Vaccines Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Shahla Shahsavandi
Poultry Research and Viral Vaccines Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Parviz Shayan
Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

Notes

Address correspondence to: Dr. Mohammad Majid Ebrahimi, Poultry Research and Viral Vaccines Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, P.O. Box 31975-148, Karaj 3197619751, Iran [email protected]

Authors' Contributions

M.M.E. performed all the experiments and interpretation of data and S.S. contributed to project management. The authors participated meaningfully in the study and have approved the final article.

Author Disclosure Statement

No competing financial interests exist.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top